The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 469 participants.
Also called NCT01106625
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 469 participants
- Registry
-
NCT01106625
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Belgium, France, Guatemala, Hungary, Israel, Mexico, Puerto Rico, Russia, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01106625. Randomized; triple masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2011-09 (actual). Results posted on 2013-05-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Canagliflozin
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Sulphonylruea
- Lead sponsor
- Janssen Research & Development, LLC
Record details
- Record id
cardio:ct-nct01106625- Content hash
8aeee36fdb4aa800c6f0911542d14995728e97babce38240ad036e73629b17d3